Dermatology Asset Acquired to Accelerate Path to Revenue

• Botanix has acquired Sofpironium Bromide gel 15%, the first and only new chemical entity developed to treat “primary axillary hyperhidrosis” – a medical condition which results in excessive underarm sweating • Sofpironium Bromide achieved statistical significance in all primary and secondary endpoints and was found to have a favourable safety profile in Phase 3 pivotal studies and in the 48-week